PCSK9: An enigmatic protease

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1781, Issue 4, 2008, Pages 184-191

  Lopez, Dayami ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

ADH; Hypercholesterolemia; Hypocholesterolemia; LDL; LDL receptor; NARC 1; PCSK9

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEINASE; UNCLASSIFIED DRUG;

HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW;

ANIMALS; APOLIPOPROTEIN B-100; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICE; MICE, KNOCKOUT; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; UP-REGULATION;

MUS;

EID: 40949136906     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2008.01.003     Document Type: Review

References (82)

1. Goldstein J., Hobbs H.H., and Brown M. In: Scriver C., Beauder A., Sly W., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York, New York 2863-2913
2. Villeger L., Abifadel M., Allard D., Rabes J.P., Thiart R., Kotze M.J., Beroud C., Junien C., Boileau C., and Varret M. The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum. Mutat. 20 (2002) 81-87
3. Boren J., Ekstrom U., Agren B., Nilsson-Ehle P., and Innerarity T.L. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J. Biol. Chem. 276 (2001) 9214-9218
4. Soufi M., Sattler A.M., Maerz W., Starke A., Herzum M., Maisch B., and Schaefer J.R. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis 174 (2004) 11-16
5. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derre A., Villeger L., Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J.M., Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C., Seidah N.G., and Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2003) 154-156
6. Allard D., Amsellem S., Abifadel M., Trillard M., Devillers M., Luc G., Krempf M., Reznik Y., Girardet J.P., Fredenrich A., Junien C., Varret M., Boileau C., Benlian P., and Rabes J.P. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat. 26 (2005) 497
7. Timms K.M., Wagner S., Samuels M.E., Forbey K., Goldfine H., Jammulapati S., Skolnick M.H., Hopkins P.N., Hunt S.C., and Shattuck D.M. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114 (2004) 349-353
8. Rader D.J., Cohen J., and Hobbs H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111 (2003) 1795-1803
9. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., Asselin M.C., Hamelin J., Varret M., Allard D., Trillard M., Abifadel M., Tebon A., Attie A.D., Rader D.J., Boileau C., Brissette L., Chretien M., Prat A., and Seidah N.G. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279 (2004) 48865-48875
10. Maxwell K.N., and Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7100-7105
11. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., and Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 928-933
12. Bergeron F., Leduc R., and Day R. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J. Mol. Endocrinol. 24 (2000) 1-22
13. Seidah N.G., and Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848 (1999) 45-62
14. Seidah N.G., and Prat A. Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem. 38 (2002) 79-94
15. Taylor N.A., Van De Ven W.J., and Creemers J.W. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J. 17 (2003) 1215-1227
16. Scamuffa N., Calvo F., Chretien M., Seidah N.G., and Khatib A.M. Proprotein convertases: lessons from knockouts. FASEB J. 20 (2006) 1954-1963
17. Seidah N.G., Mowla S.J., Hamelin J., Mamarbachi A.M., Benjannet S., Toure B.B., Basak A., Munzer J.S., Marcinkiewicz J., Zhong M., Barale J.C., Lazure C., Murphy R.A., Chretien M., and Marcinkiewicz M. Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1321-1326
18. Espenshade P.J., Cheng D., Goldstein J.L., and Brown M.S. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 274 (1999) 22795-22804
19. Hunt S.C., Hopkins P.N., Bulka K., McDermott M.T., Thorne T.L., Wardell B.B., Bowen B.R., Ballinger D.G., Skolnick M.H., and Samuels M.E. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1089-1093
20. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., and Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1454-1459
21. Grozdanov P.N., Petkov P.M., Karagyozov L.K., and Dabeva M.D. Expression and localization of PCSK9 in rat hepatic cells. Biochem. Cell. Biol. 84 (2006) 80-92
22. Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y., Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D., DiStefano P.S., Wood A., and Bingham B. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 420 (2003) 55-67
23. Jain S.C., Shinde U., Li Y., Inouye M., and Berman H.M. The crystal structure of an autoprocessed Ser221Cys-subtilisin E-propeptide complex at 2.0 Å resolution. J. Mol. Biol. 284 (1998) 137-144
24. Hampton E.N., Knuth M.W., Li J., Harris J.L., Lesley S.A., and Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14604-14609
25. Cunningham D., Danley D.E., Geoghegan K.F., Griffor M.C., Hawkins J.L., Subashi T.A., Varghese A.H., Ammirati M.J., Culp J.S., Hoth L.R., Mansour M.N., McGrath K.M., Seddon A.P., Shenolikar S., Stutzman-Engwall K.J., Warren L.C., Xia D., and Qiu X. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14 (2007) 413-419
26. Piper D.E., Jackson S., Liu Q., Romanow W.G., Shetterly S., Thibault S.T., Shan B., and Walker N.P. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15 (2007) 545-552
27. Park S.W., Moon Y.A., and Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279 (2004) 50630-50638
28. Humphries S.E., Whittall R.A., Hubbart C.S., Maplebeck S., Cooper J.A., Soutar A., Naoumova R., Thompson G.R., Seed M., Durrington P.N., Miller J.P., Betteridge D.J., and Neil H.A. Genetic causes of familial hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43 (2006) 943-949
29. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., Cohen J.C., and Hobbs H.H. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79 (2006) 514-523
30. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Wook Park S., Prather H.B., Anderson N.N., Ho Y.K., Hammer R.E., and Horton J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in liver of parabiotic mice. J. Clin. Invest. 116 (2006) 2995-3005
31. Qian Y.W., Schmidt R.J., Zhang Y., Chu S., Lin A., Wang H., Wang X., Beyer T.P., Bensch W.R., Li W., Ehsani M.E., Lu D., Konrad R.J., Eacho P.I., Moller D.E., Karathanasis S.K., and Cao G. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 48 (2007) 1488-1498
32. Mayne J., Raymond A., Chaplin A., Cousins M., Kaefer N., Gyamera-Acheampong C., Seidah N.G., Mbikay M., Chretien M., and Ooi T.C. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem. Biophys. Res. Commun. 361 (2007) 451-456
33. Benjannet S., Rhainds D., Hamelin J., Nassoury N., and Seidah N.G. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A. Functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281 (2006) 30561-30572
34. Maxwell K.N., Soccio R.E., Duncan E.M., Sehayek E., and Breslow J.L. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44 (2003) 2109-2119
35. Costet P., Cariou B., Lambert G., Lalanne F., Lardeux B., Jarnoux A.L., Grefhorst A., Staels B., and Krempf M. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J. Biol. Chem. 281 (2006) 6211-6218
36. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., and Goldstein J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12027-12032
37. Schmidt R.J., Ficorilli J.V., Zhang Y., Bramlett K.S., Beyer T.P., Borchert K., Dowless M.S., Houck K.A., Burris T.P., Eacho P.I., Liang G., Guo L.W., Wilson W.K., Michael L.F., and Cao G. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. J. Lipid Res. 47 (2006) 1037-1044
38. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., and Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin kexin type 9 (PCSK9). J. Lipid Res. 49 (2008) 394-398
39. Bedi M., Niesen M., and Lopez D. Inhibition of squalene synthase upregulates PCSK9 expression in rat liver. Arch. Biochem. Biophys. 470 (2008) 116-119
40. Nilsson L.M., Abrahamsson A., Sahlin S., Gustafsson U., Angelin B., Parini P., and Einarsson C. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem. Biophys. Res. Commun. 357 (2007) 707-711
41. Niesen M., Bedi M., and Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch. Biochem. Biophys. 470 (2008) 111-115
42. Lambert G., Jarnoux A.L., Pineau T., Pape O., Chetiveaux M., Laboisse C., Krempf M., and Costet P. Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology 147 (2006) 4985-4995
43. Homer V.M., Marais A.D., Charlton F., Laurie A.D., Hurndell N., Scott R., Mangili F., Sullivan D.R., Barter P.J., Rye K.A., George P.M., and Lambert G. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 196 (2008) 659-666
44. Cameron J., Holla O.L., Ranheim T., Kulseth M.A., Berge K.E., and Leren T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15 (2006) 1551-1558
45. Jeon H., Meng W., Takagi J., Eck M.J., Springer T.A., and Blacklow S.C. Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat. Struct. Biol. 8 (2001) 499-504
46. Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J., Poupon V., McPherson P.S., Attie A.D., Prat A., and Seidah N.G. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8 (2007) 718-732
47. Chen S.N., Ballantyne C.M., Gotto A.M., Tan Y., Willerson J.T., and Marian A.J. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J. Am. Coll. Cardiol. 45 (2005) 1611-1619
48. Evans D., and Beil F.U. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med. Genet. 7 (2006) 66
49. Abboud S., Karhunen P.J., Lutjohann D., Goebeler S., Luoto T., Friedrichs S., Lehtimaki T., Pandolfo M., and Laaksonen R. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS ONE 2 (2007) e1043
50. Scartezini M., Hubbart C., Whittall R.A., Cooper J.A., Neil A.H., and Humphries S.E. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin. Sci. (Lond) 113 (2007) 435-441
51. Hallman D.M., Srinivasan S.R., Chen W., Boerwinkle E., and Berenson G.S. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am. J. Cardiol. 100 (2007) 69-72
52. Cohen J.C., Boerwinkle E., Mosley T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 (2006) 1264-1272
53. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., and Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37 (2005) 161-165
54. Hooper A.J., Marais A.D., Tanyanyiwa D.M., and Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193 (2007) 445-448
55. Fielding C.J., Bist A., and Fielding P.E. Uptake of lipoprotein free cholesterol and its intracellular transport. In: Chang T.Y., and Freeman D.A. (Eds). Intracellular Cholesterol Trafficking (1998), Kluwer Academic Publishers, Boston, MA 273-288
56. Fielding P.E., and Fielding C.J. Intracellular transport of low density lipoprotein derived free cholesterol begins at clathrin-coated pits and terminates at cell surface caveolae. Biochemistry 35 (1996) 14932-14938
57. Gent J., and Braakman I. Low-density lipoprotein receptor structure and folding. Cell. Mol. Life Sci. 61 (2004) 2461-2470
58. Chen W.J., Goldstein J.L., and Brown M.S. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J. Biol. Chem. 265 (1990) 3116-3123
59. Davis C.G., Lehrman M.A., Russell D.W., Anderson R.G., Brown M.S., and Goldstein J.L. The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell 45 (1986) 15-24
60. He G., Gupta S., Yi M., Michaely P., Hobbs H.H., and Cohen J.C. ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin and AP-2. J. Biol. Chem. 277 (2002) 44044-44049
61. Mishra S.K., Watkins S.C., and Traub L.M. The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16099-16104
62. Rudenko G., Henry L., Henderson K., Ichtchenko K., Brown M.S., Goldstein J.L., and Deisenhofer J. Structure of the LDL receptor extracellular domain at endosomal pH. Science 298 (2002) 2353-2358
63. Brown M.S., Anderson R.G., and Goldstein J.L. Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell 32 (1983) 663-667
64. Beglova N., and Blacklow S.C. The LDL receptor: how acid pulls the trigger. Trends Biochem. Sci. 30 (2005) 309-317
65. Beglova N., Jeon H., Fisher C., and Blacklow S.C. Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor. Mol. Cell 16 (2004) 281-292
66. Lopez D., Chambers C.M., Keller R.K., and Ness G.C. Compensatory responses to inhibition of hepatic squalene synthase. Arch. Biochem. Biophys. 351 (1998) 159-166
67. Ness G.C., Zhao Z., and Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch. Biochem. Biophys. 325 (1996) 242-248
68. McNutt M.C., Lagace T.A., and Horton J.D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282 (2007) 20799-20803
69. Li J., Tumanut C., Gavigan J.A., Huang W.J., Hampton E.N., Tumanut R., Suen K.F., Trauger J.W., Spraggon G., Lesley S.A., Liau G., Yowe D., and Harris J.L. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406 (2007) 203-207
70. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., Cohen J.C., and Hobbs H.H. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282 (2007) 18602-18612
71. Fisher T.S., Lo Surdo P., Pandit S., Mattu M., Santoro J.C., Wisniewski D., Cummings R.T., Calzetta A., Cubbon R.M., Fischer P.A., Tarachandani A., De Francesco R., Wright S.D., Sparrow C.P., Carfi A., and Sitlani A. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem. 282 (2007) 20502-20512
72. Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., Mayer H., Nimpf J., Prat A., and Seidah N.G. The proprotein convertase PCSK9 induces the degradation of LDLR and its closest family members VLDLR and APOER2. J. Biol. Chem. 283 (2008) 2363-2372
73. Holla O.L., Cameron J., Berge K.E., Ranheim T., and Leren T.P. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol. 8 (2007) 9
74. Anderson R.G.W., Brown M.S., and Goldstein J.L. Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell 10 (1977) 351-364
75. Riddell D.R., Sun X.M., Stannard A.K., Soutar A.K., and Owen J.S. Localization of apolipoprotein E receptor 2 to caveolae in the plasma membrane. J. Lipid Res. 42 (2001) 998-1002
76. Ness G.C., Kohlruss N., and Gertz K.R. Association of the low-density lipoprotein receptor with caveolae in hamster and rat liver. Biochem. Biophys. Res. Comm. 303 (2003) 177-181
77. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., Boileau C., Magot T., and Krempf M. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1448-1453
78. Sun X.M., Eden E.R., Tosi I., Neuwirth C.K., Wile D., Naoumova R.P., and Soutar A.K. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum. Mol. Genet. 14 (2005) 1161-1169
79. Naoumova R.P., Tosi I., Patel D., Neuwirth C., Horswell S.D., Marais A.D., van Heyningen C., and Soutar A.K. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2654-2660
80. Gillian-Daniel D.L., Bates P.W., Tebon A., and Attie A.D. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4337-4342
81. Horton J.D., Shimano H., Hamilton R.L., Brown M.S., and Goldstein J.L. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103 (1999) 1067-1076
82. Twisk J., Gillian-Daniel D.L., Tebon A., Wang L., Barrett P.H., and Attie A.D. The role of the LDL receptor in apolipoprotein B secretion. J. Clin. Invest. 105 (2000) 521-532